Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six‐year follow‐up study.

Pajno, Giovanni Battista; Barberio, G; Luca, Fr. De; Morabito, L.; Parmiani, S.

doi:10.1046/j.1365-2222.2001.01161.x

Cited by 494 publications

(344 citation statements)

References 22 publications

Supporting

Mentioning

315

Contrasting

Unclassified

Order By: Relevance

“…It represents a realistic and potentially disease-modifying therapeutic approach for the treatment of allergic and autoimmune diseases with strong CD4 + T-cell components to their pathogenesis, such as allergic asthma (3)(4)(5). Traditional immunotherapy, using whole-protein antigens, is associated with the risk of severe allergic reactions, particularly anaphylaxis, in patients harboring allergen-reactive IgE (6,7).…”

mentioning

confidence: 99%

Effector and central memory T helper 2 cells respond differently to peptide immunotherapy

Mackenzie

Nowakowska

Leech

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Peptide immunotherapy (PIT) offers realistic prospects for the treatment of allergic diseases, including allergic asthma. Much is understood of the behavior of naive T cells in response to PIT. However, treatment of patients with ongoing allergic disease requires detailed understanding of the responses of allergenexperienced T cells. CD62L expression by allergen-experienced T cells corresponds to effector/effector memory (CD62L lo ) and central memory (CD62L hi ) subsets, which vary with allergen exposure (e.g., during, or out with, pollen season). The efficacy of PIT on different T helper 2 (Th2) cell memory populations is unknown. We developed a murine model of PIT in allergic airway inflammation (AAI) driven by adoptively transferred, traceable ovalbumin-experienced Th2 cells. PIT effectively suppressed AAI driven by unfractionated Th2 cells. Selective transfer of CD62L hi and CD62L lo Th2 cells revealed that these two populations behaved differently from one another and from previously characterized (early deletional) responses of naive CD4 + T cells to PIT. Most notably, allergen-reactive CD62L lo Th2 cells were long-lived within the lung after PIT, before allergen challenge, in contrast to CD62L hi Th2 cells. Despite this, PIT was most potent against CD62L lo Th2 cells in protecting from AAI, impairing their ability to produce Th2 cytokines, whereas this capacity was heightened in PIT-treated CD62L hi Th2 cells. We conclude that Th2 cells do not undergo an early deletional form of tolerance after PIT. Moreover, memory Th2 subsets respond differently to PIT. These findings have implications for the clinical translation of PIT in different allergic scenarios.

show abstract

mentioning

confidence: 99%

Effector and central memory T helper 2 cells respond differently to peptide immunotherapy

Mackenzie

Nowakowska

Leech

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…Our search strategy identified 1378 unique publications, including over 338 peer-reviewed studies published from inception to June 30, 2015 finally retrieved , of which 18 met the inclusion criteria (20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37). We excluded the Jacobsen study (38), because the outcome was reported in a subgroup of patients regardless of the treatment received, the Eifan (39) Acquistapace (40), Szepfalusi (41), and Shao (42) studies because they were not long-term studies (<3 years of treatment/follow-up).…”

Section: Resultsmentioning

confidence: 99%

“…Table 1 shows descriptive data for the 18 systematically reviewed studies (20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37). [11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] and seven adult studies (31-37) included a total of 11 106 patients (1049 children, 10 057 adults), of which 8369 (75.6%) were included only in the Purello D'Ambrosio study (31). Nine of 18 studies were conducted in Italy (21,22,24,25,29,31,(33)(34)(35), four in Turkey, and (26)…”

Section: Resultsmentioning

confidence: 99%

Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review

Bona

Plaia

Leto-Barone

et al. 2017

Allergy

View full text Add to dashboard Cite

Background: Guidelines and position papers indicate that allergen immunotherapy (AIT) is the only disease-modifying treatment, including prevention of the onset of new allergen sensitizations. However, this preventive effect was shown by only a few observational studies. Our aim was to systematically review the efficacy of AIT in preventing the onset of new allergen sensitizations. Methods: Computerized bibliographic searches of Medline, EMBASE, and the Cochrane Library (through June 2015) were supplemented with manual searches of reference lists. Observational studies or randomized controlled trials with a longterm observation period were included. Paired reviewers extracted data about study characteristics and assessed biases. The end point was the risk difference in the onset of new allergen sensitizations between patients treated with AIT and pharmacotherapy. The strength of the evidence was graded based on the risk of bias, consistency, and magnitude of effect, according to the GRADE Working Group's guide. Results: Eighteen studies (1049 children, 10 057 adults) met the inclusion criteria. The risk of bias was high in all but one study. Low evidence supports the position that AIT prevents the onset of new allergen sensitizations, with 10 of 18 studies reporting a reduction in the onset of new sensitizations in patients treated with AIT vs placebo. Small studies and studies with a shorter follow-up showed the highest benefit of AIT. Conclusions: The overall evidence provides a low-grade level of the evidence supporting the efficacy of AIT in preventing the onset of new allergen sensitizations, but high-quality studies could change this estimate.

show abstract

“…First, at variance with drugs, SIT can modify the natural history of allergic disease, as recently confirmed in rigorously conducted trials such as the PAT (7), whose results are to be published soon. Second, SIT can prevent the onset of new sensitizations, as demonstrated clearly in children in several studies (8)(9)(10). Third, SIT even maintains its clinical efficacy years after discontinuation.…”

mentioning

confidence: 89%

Long‐lasting clinical efficacy of allergen specific immunotherapy

Passalacqua¹,

Canonica²

2002

Allergy

View full text Add to dashboard Cite

Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six‐year follow‐up study.

Abstract: According to our data, SIT may prevent the onset of new sensitizations in children with respiratory symptoms monosensitized to house dust mite (HDM).

Cited by 494 publications

References 22 publications

Effector and central memory T helper 2 cells respond differently to peptide immunotherapy

Effector and central memory T helper 2 cells respond differently to peptide immunotherapy

Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review

Long‐lasting clinical efficacy of allergen specific immunotherapy

Contact Info

Product

Resources

About